Cochlear Ltd (ASX: COH) shares are mounting an impressive comeback.
The hearing implant leader has climbed 11% over the past five trading sessions to $127.86, at the time of writing. That takes its gain over the past month to an impressive 32%. Even so, the healthcare stock remains down 51% year to date after one of the biggest sell-offs seen on the ASX this year.
So, has the worst passed, or is this simply a relief rally?
Image source: Getty Images
What do brokers think?
Broker sentiment remains cautious, but few analysts appear ready to give up on Cochlear. According to TradingView data, most brokers currently rate Cochlear shares as a hold. The average 12-month price target sits at $127.33, only slightly below the current share price, suggesting analysts see limited upside in the near term.
Of the 18 brokers covering the company, six rate the stock as either a buy or strong buy. The most optimistic analyst expects the shares to climb another 33% over the next year. At the other end of the spectrum, two brokers recommend selling the stock. The lowest price target sits at $95, implying downside of around 25%.
Bell Potter is among those taking a balanced approach. The broker continues to recommend holding Cochlear shares, arguing the company's long-term outlook remains attractive thanks to its dominant market position, significant growth opportunity and continued product innovation.
Why did Cochlear shares crash?
To understand the recent rebound, it's important to remember what caused the sell-off in the first place. On 22 April, Cochlear shocked the market with a disappointing trading update that sparked one of the largest one-day declines on the ASX this year.
Management reported weaker-than-expected demand for hearing implants across developed markets. At the same time, ongoing conflict in the Middle East led to order cancellations and shipment delays, adding further pressure to earnings.
The company also slashed its FY26 underlying net profit guidance to between $290 million and $330 million, well below its previous forecast of $435 million to $460 million. Investors responded swiftly, sending Cochlear shares tumbling by more than 40% in a single session.
Since then, the market has been trying to answer one question: was this a temporary disruption or a sign of a more structural slowdown?
Is the long-term growth story still intact?
Despite the earnings downgrade, Cochlear's competitive position remains difficult to challenge.
The company controls around half of the global cochlear implant market, giving it a leadership position built on decades of research, innovation and close relationships with surgeons and healthcare providers. Its products are deeply embedded within healthcare systems around the world, creating significant barriers for competitors.
The long-term growth opportunity also remains substantial. More than six million people across developed markets are estimated to be eligible for cochlear implants, yet only around 3% currently receive one. As awareness improves, diagnosis rates increase and technology advances, that penetration rate has considerable room to grow.
An ageing global population is expected to provide another powerful tailwind over the coming decades.
